[
    {
        "category": "company",
        "datetime": 1743525000,
        "headline": "Biogen Inc. stock outperforms competitors despite losses on the day",
        "id": 133684591,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock outperforms competitors despite losses on the day",
        "url": "https://finnhub.io/api/news?id=240b485c7141033328c9a80affc35bbdb00e7b6d546fc4f6635d13a9e5ad03b8"
    },
    {
        "category": "company",
        "datetime": 1743502336,
        "headline": "Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years",
        "id": 133646017,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big...",
        "url": "https://finnhub.io/api/news?id=c16c01d50792902a01ab1906497063f81c33534d63e916bb8d83a321205dd036"
    },
    {
        "category": "company",
        "datetime": 1743487996,
        "headline": "Biogen : Update on Regulatory Review of Lecanemab for Early Alzheimer\u2019s Disease by the European Commission",
        "id": 133633957,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., April 1, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a...",
        "url": "https://finnhub.io/api/news?id=ae46f2afbff3a760f211cf1693915b363b959249ca3d1990122a67f3962b3a45"
    },
    {
        "category": "company",
        "datetime": 1743440820,
        "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
        "id": 133650967,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=2507f0c20b08cf4fd8fdbc3c34a2776e80d1b78c433f8e8a42db3548109565d3"
    },
    {
        "category": "company",
        "datetime": 1743181560,
        "headline": "Biogen Inc. stock underperforms Friday when compared to competitors",
        "id": 133650968,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Friday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=5c76500d8d696aed76040703c844f76dff22116936537edebf9ff4683e1f94dd"
    },
    {
        "category": "company",
        "datetime": 1743123300,
        "headline": "ClearBridge Growth ESG Portfolios Q4 2024 Commentary",
        "id": 133504563,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054522581/image_2054522581.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "A market broadening in the fourth quarter sparked by Donald Trump\u00e2\u0080\u0099s election victory and a further interest rate cut from the US Federal Reserve proved momentum-driven and short-lived.",
        "url": "https://finnhub.io/api/news?id=6b0ea926305a2a4ba933c3161d88aa79688369656de128124c20e105b3f2a570"
    },
    {
        "category": "company",
        "datetime": 1743095280,
        "headline": "Biogen Inc. stock underperforms Thursday when compared to competitors",
        "id": 133500037,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=de60dd6776fca0fe49163da197e5956e1b004466aad4d824958bf014d629e0dc"
    },
    {
        "category": "company",
        "datetime": 1743092089,
        "headline": "Biogen: Balancing Risks And Opportunities",
        "id": 133485407,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/911834392/image_911834392.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.",
        "url": "https://finnhub.io/api/news?id=8a8e09bd768e3af197af3a611ae16b216a2076e35880cf093b662d265d5070c6"
    },
    {
        "category": "company",
        "datetime": 1743066000,
        "headline": "Lilly adds Alzheimer's to online offerings",
        "id": 133470265,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Eli Lilly on Thursdayexpanded its direct-to-consumer online platform LillyDirect toinclude telehealth providers to diagnose and care for patientswith Alzheimer's disease, potentially boosting sales...",
        "url": "https://finnhub.io/api/news?id=aa65e90d2c3eefd061943ad1e63e0e2c591cfdbfd78450c708a6dfaa4e15dadd"
    },
    {
        "category": "company",
        "datetime": 1743008820,
        "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
        "id": 133500038,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=80c65f705584625768bce28e2471dfbff6b3c112a07db563218ea36910010770"
    },
    {
        "category": "company",
        "datetime": 1742922480,
        "headline": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
        "id": 133500039,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Tuesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=726bc25137e0f0af2f19dd8a400505c2047bbbf891c687f7ac1ce88665e56a68"
    },
    {
        "category": "company",
        "datetime": 1742919254,
        "headline": "BIOGEN : TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS MAY 1, 2025",
        "id": 133403610,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cambridge, Mass.- Biogen Inc. today announced it will report first quarter 2025 financial results Thursday, May 1, 2025, before the financial markets open. Following the release...",
        "url": "https://finnhub.io/api/news?id=8ded0e3df9197ecdaf7461d2186eb56d2b6cfd95546b4dc0a6c8dc27a8721f53"
    },
    {
        "category": "company",
        "datetime": 1742895488,
        "headline": "Cassava Sciences shuts down Alzheimer's program - shares plummet",
        "id": 133375018,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cassava Science's shares fell more than 20 percent in early trading in the United States on the news that the company is discontinuing its program to develop a drug for Alzheimer's. The program will...",
        "url": "https://finnhub.io/api/news?id=0ba6bc731967918d617c6fbd96d86d07e9edc0bb59a44fbbe7f4d86d027f250e"
    },
    {
        "category": "company",
        "datetime": 1742821347,
        "headline": "3 Value Stocks Walking a Fine Line",
        "id": 133338167,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
        "url": "https://finnhub.io/api/news?id=4304d252356126fa21d7f23247bc46f8f1d6b2af1607c5ae06fc92ef3dee679e"
    },
    {
        "category": "company",
        "datetime": 1742817480,
        "headline": "Biogen plots new global headquarters in Kendall Square",
        "id": 133350002,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in \u201cKendall Commons,\u201d a development project spearheaded by MIT.",
        "url": "https://finnhub.io/api/news?id=a696ea7f443a86ff5541cbd58a9b5d07383c0c8952ee5d3c38539c2c41911687"
    },
    {
        "category": "company",
        "datetime": 1742815800,
        "headline": "Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square",
        "id": 133338168,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprintNew building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cam",
        "url": "https://finnhub.io/api/news?id=5f1e9a091acd0f99d5b95fb3ddd9ca676f9242e86c54f81f4d056f9bf5bf4baf"
    },
    {
        "category": "company",
        "datetime": 1742484626,
        "headline": "Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?",
        "id": 133327023,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=86ea023229c5572821648691a4270ce4d51a9b631037fdfc87d2c9526ac2e02d"
    },
    {
        "category": "company",
        "datetime": 1742461970,
        "headline": "Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
        "id": 133325405,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Let\u2019s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.",
        "url": "https://finnhub.io/api/news?id=661997f746daf698d0000c7f7328d3e6c49fc655d722e02e6e14965810a8bc71"
    },
    {
        "category": "company",
        "datetime": 1742403960,
        "headline": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
        "id": 133284318,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=3882ad9cb06040d6a8d4b62eb6a9cff7c522e288ebc39b5f55f5e7bfa53f6994"
    },
    {
        "category": "company",
        "datetime": 1742394645,
        "headline": "Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In",
        "id": 133327025,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other most undervalued biotech stocks to invest in. Trump\u2019s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho Securities America\u2019s [\u2026]",
        "url": "https://finnhub.io/api/news?id=b1709660476cdea94e662f24fd2e4ad0a2ecf6c48bef56f945e3ff4c21cff1b7"
    },
    {
        "category": "company",
        "datetime": 1742308764,
        "headline": "Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)",
        "id": 133234616,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ETCompany ParticipantsPriya Singhal - Head of...",
        "url": "https://finnhub.io/api/news?id=370855ca130143ac73cb2156615c7ece21d4cd6f212c64a49957eb6fdfbb65e5"
    },
    {
        "category": "company",
        "datetime": 1742297727,
        "headline": "Health Canada approves Biogen\u2019s Skyclarys for Friedreich\u2019s ataxia",
        "id": 133327026,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The approval of the therapy is supported by the pivotal, placebo-controlled MOXIe Part 2 trial.",
        "url": "https://finnhub.io/api/news?id=51bcd5f3a264dc154bc3dc376745cdddc39a0c691b523fbf2ec5daa5818ee214"
    },
    {
        "category": "company",
        "datetime": 1742217960,
        "headline": "Robinhood, Home Depot, and More Stocks for the \u2018Silver Tsunami\u2019 of Older Shoppers",
        "id": 134146945,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Robinhood, Home Depot, and More Stocks for the \u2018Silver Tsunami\u2019 of Older Shoppers",
        "url": "https://finnhub.io/api/news?id=b1b293a7472e3f48abdc38186820c5dfca2baa850331b9fa975fa30760eb14d0"
    },
    {
        "category": "company",
        "datetime": 1742195896,
        "headline": "Biogen Canada's Skyclarys Approved By Health Canada To Treat Friedreich's Ataxia In Patients 16 Years Of Age And Older",
        "id": 133206253,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Biogen Inc: * BIOGEN CANADA: HEALTH CANADA APPROVES SKYCLARYS TO TREATFRIEDREICH'S ATAXIA IN PATIENTS 16 YEARS OF AGE AND OLDERSource text:Further company coverage: ...",
        "url": "https://finnhub.io/api/news?id=3b08a6d96462a8385638204ebe77b1c9554991529cab6c7f5335ff903caf237e"
    },
    {
        "category": "company",
        "datetime": 1741966235,
        "headline": "Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?",
        "id": 133185352,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=82271ce54ea5345b9142c7d260fc5faf0b5c2e296a6299fa7ec4c963996eda9d"
    },
    {
        "category": "company",
        "datetime": 1741961322,
        "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
        "id": 133184265,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
        "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2"
    },
    {
        "category": "company",
        "datetime": 1741959600,
        "headline": "Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?",
        "id": 133191249,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?",
        "url": "https://finnhub.io/api/news?id=50ce28934705859f25b678dfe2b97d74e33fb2a303d230fc72b67034a56bea08"
    },
    {
        "category": "company",
        "datetime": 1741795920,
        "headline": "BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant",
        "id": 133191250,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.",
        "url": "https://finnhub.io/api/news?id=19a27ed80ed2ea9b06cc5af44147043a2de6ed981e306358ea3b37dd855c8749"
    },
    {
        "category": "company",
        "datetime": 1741780047,
        "headline": "Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR",
        "id": 133191251,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.",
        "url": "https://finnhub.io/api/news?id=df483530e6c6ec9628ca2140df1d11a3209339b128ea65778b2593da11d334ea"
    },
    {
        "category": "company",
        "datetime": 1741711163,
        "headline": "Biogen : to Participate in the Stifel 2025 Virtual CNS Forum",
        "id": 133139357,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cambridge, MA, - - Biogen Inc. announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in a fireside chat during the Stifel 2025 Virtual CNS Forum. The webcast will be...",
        "url": "https://finnhub.io/api/news?id=29cb35fc3b571081085a2157fee9e4eae1a9ec147f388a13d39323234e3c1d6c"
    },
    {
        "category": "company",
        "datetime": 1741692600,
        "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients",
        "id": 133191252,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the U.S1Felzartamab, with demonstrated proof of concept in multiple immune-mediated diseases, represents a key asset in Biogen\u2019s late-stage immunology portfolio CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) \u2013 announced",
        "url": "https://finnhub.io/api/news?id=d65557b14f2672254399427444822260c1d808fe9b97c76cef4b5cf429234aa1"
    },
    {
        "category": "company",
        "datetime": 1741629757,
        "headline": "Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)",
        "id": 133128095,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of North...",
        "url": "https://finnhub.io/api/news?id=7aa90a5cc6a2f3f15d5a24704c1392509d323f335b2f8af54d24ec57e5807423"
    },
    {
        "category": "company",
        "datetime": 1741340400,
        "headline": "ClearBridge All Cap Growth Strategy Q4 2024 Commentary",
        "id": 133090333,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413858192/image_1413858192.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=81b2942b352a432f4c8934f624e12169c63abda471c2d5a524050f1bd70c8ce0"
    },
    {
        "category": "company",
        "datetime": 1741107750,
        "headline": "Tariffs Send Investors to Safety of Food, Drug and Utility Stocks",
        "id": 133191253,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "As market turmoil picks up, industries selling products that consumers rely on regardless of economic conditions are emerging as safe havens.  Healthcare, utilities, and consumer staples rallied, extending their gains for the year as concerns over tariffs and a potential recession mounted.  Biogen, Merck, General Mills, McDonald\u2019s and Hershey were among the S&P 500\u2019s top gainers.",
        "url": "https://finnhub.io/api/news?id=bf3d3aaa5243b3de10cfaa81ff83ac2811884fc583c45040e5b074a96ae6edc2"
    },
    {
        "category": "company",
        "datetime": 1741072317,
        "headline": "New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer\u2019s approach",
        "id": 133191254,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Voyager Therapeutics\u2019 progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.",
        "url": "https://finnhub.io/api/news?id=82bbd52bc58ecde29b96b3aee27a412881e4675b0c0d9a83b77b63f7b01b89a6"
    },
    {
        "category": "company",
        "datetime": 1741026575,
        "headline": "Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)",
        "id": 132969829,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference Call...",
        "url": "https://finnhub.io/api/news?id=84b2de5e1dc7132122621811f6145c56e2731e74012cf0800d4aa3895e0f2efe"
    },
    {
        "category": "company",
        "datetime": 1740992555,
        "headline": "3 Reasons BIIB is Risky and 1 Stock to Buy Instead",
        "id": 133191255,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and might have investors contemplating their next move.",
        "url": "https://finnhub.io/api/news?id=a8ff92ce0fe62bf79d8f931df48a039226748d5675f9a10e1a33016af06de885"
    },
    {
        "category": "company",
        "datetime": 1740988856,
        "headline": "Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'",
        "id": 132962661,
        "image": "",
        "related": "BIIB",
        "source": "DowJones",
        "summary": "Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'",
        "url": "https://finnhub.io/api/news?id=1cfe2a983cb0cfd9bb2d06937f8b092ad94613d4f2bea208da29f72973aafc87"
    },
    {
        "category": "company",
        "datetime": 1740970744,
        "headline": "Biogen : Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer\u2019s Disease in Australia",
        "id": 132947927,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., March 3, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration of Australia has confirmed the initial decision to decline the...",
        "url": "https://finnhub.io/api/news?id=91fd3637d015fbc0901c58c8a6aeb1bac6d1731cf01a72917a61cb15ad535e54"
    },
    {
        "category": "company",
        "datetime": 1740748980,
        "headline": "The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease",
        "id": 133191256,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-A\u03b2 monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional inform",
        "url": "https://finnhub.io/api/news?id=67d5571436f76834b82eaa99ac7df2d7ed6d3c15ff9c1f4f575ea7ae7fc4d07a"
    },
    {
        "category": "company",
        "datetime": 1740737298,
        "headline": "Biogen, Eisai : CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
        "id": 132905813,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi....",
        "url": "https://finnhub.io/api/news?id=be78faba6a29d22c37f5d1fe51c42446080a58ce0bfea13271def4feeafd7b4e"
    },
    {
        "category": "company",
        "datetime": 1740736320,
        "headline": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
        "id": 132922082,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
        "url": "https://finnhub.io/api/news?id=ae068a80e66ed4412af28fdede036c89edc9efa1912c8261f048e45d500fc1de"
    },
    {
        "category": "company",
        "datetime": 1740731444,
        "headline": "Biogen : The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer\u2019s Disease",
        "id": 132905223,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., February 28, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...",
        "url": "https://finnhub.io/api/news?id=9eb307e4db3dfa9c42f14ffc0a0fe75e28c9d0eb255d91053ff3bd8f88e257d1"
    },
    {
        "category": "company",
        "datetime": 1740730618,
        "headline": "EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes",
        "id": 132905146,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status....",
        "url": "https://finnhub.io/api/news?id=5ab8089bc309eab58ee5a9e4dfdbddc3b1c7dd726beb7a05c9750c56c0b42e9a"
    },
    {
        "category": "company",
        "datetime": 1740729289,
        "headline": "EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug",
        "id": 132904969,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "European Union's human medicines committee said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November. ...",
        "url": "https://finnhub.io/api/news?id=1a04df2d01d1d8b5cc07f2ab62407287e96a0ef46fc3076f5eb5d5f261ff8834"
    },
    {
        "category": "company",
        "datetime": 1740720000,
        "headline": "Under The Microscope: Looking For Opportunity Among Healthcare's Underperformers",
        "id": 132904137,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Many stocks in the healthcare sector have trailed the wider markets, but are there pockets of opportunity? TD Asset Management's Ram Sampath discusses.",
        "url": "https://finnhub.io/api/news?id=ee89c0cbe9506e056ebf3d083277e9ebea494a171c6235d0e9374fc1537447f6"
    },
    {
        "category": "company",
        "datetime": 1740650974,
        "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
        "id": 132900099,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795327693/image_1795327693.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
        "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43"
    },
    {
        "category": "company",
        "datetime": 1740503974,
        "headline": "Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts",
        "id": 133191257,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. The Stock Market Under Trump Admin While stocks initially fell based on worries regarding Trump tariffs on America\u2019s [\u2026]",
        "url": "https://finnhub.io/api/news?id=bd3e53aee7e5f71cce93657ab9b4cba33d1c31355a75060830526cb4598ac635"
    },
    {
        "category": "company",
        "datetime": 1740418773,
        "headline": "NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects",
        "id": 133191258,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc\u2019s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects. At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization. Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic\u2019s Dra",
        "url": "https://finnhub.io/api/news?id=378e1260615827cfc4d736e9f230f9e257e5ccbb065b2a2af43c15902e68981a"
    },
    {
        "category": "company",
        "datetime": 1740414067,
        "headline": "Biogen : to Participate in the TD Cowen 45th Annual Health Care Conference",
        "id": 132865852,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cambridge, MA, - - Biogen Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the TD Cowen 45th Annual Health Care...",
        "url": "https://finnhub.io/api/news?id=1d0fd8c8b5dc7475dbcf06900281d80b3055f6042a4d103cbbc0ae2b9ec6af81"
    },
    {
        "category": "company",
        "datetime": 1740405840,
        "headline": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
        "id": 134161433,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency",
        "url": "https://finnhub.io/api/news?id=cdffe168c1ec41691900223c672589359d0772921c2def59f987acc0c838d6b7"
    },
    {
        "category": "company",
        "datetime": 1740286048,
        "headline": "Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts",
        "id": 133191259,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. The Evolving Landscape of Healthcare and Biopharma Innovation Almost no other industry goes as far as the phrase \u201cdefensive\u201d [\u2026]",
        "url": "https://finnhub.io/api/news?id=c128a264118052ee430c9904a94da86505cddc069de407857b31fe3f11696bf3"
    },
    {
        "category": "company",
        "datetime": 1739976042,
        "headline": "Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval",
        "id": 132790634,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1914834329/image_1914834329.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a must-watch. Read more on IONS stock here.",
        "url": "https://finnhub.io/api/news?id=c147bb3682f8801342414e0c14009394d6ffbd5f6cd03234c4043a82013f96c7"
    },
    {
        "category": "company",
        "datetime": 1739966153,
        "headline": "Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment",
        "id": 133191260,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.",
        "url": "https://finnhub.io/api/news?id=a53e3f2d4cb44040ef8a777ee8be9ce76cb2a5ba6837a11bf2837e748d8f53f7"
    },
    {
        "category": "company",
        "datetime": 1739963545,
        "headline": "We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative",
        "id": 133191261,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen Inc.'s ( NASDAQ:BIIB ) recent earnings report didn't offer any surprises, with the shares unchanged over the...",
        "url": "https://finnhub.io/api/news?id=615a7597099aa74cccc44564c96f628f0ff0b81905f90ff640bd7872a54dc74d"
    },
    {
        "category": "company",
        "datetime": 1739903543,
        "headline": "Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal",
        "id": 133191262,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignm",
        "url": "https://finnhub.io/api/news?id=ce97f1c65ffe3f0d13d0ff332303495049d386f281b5106279962a90201d05d7"
    },
    {
        "category": "company",
        "datetime": 1739883600,
        "headline": "Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments",
        "id": 133191263,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen\u2019s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and",
        "url": "https://finnhub.io/api/news?id=43a027ab7f24f3bccd08f831bc1120e1ca690e911b39501a3d3155e32b81f57d"
    },
    {
        "category": "company",
        "datetime": 1739881500,
        "headline": "Biogen buys rights to Stoke\u2019s rare epilepsy drug",
        "id": 133191264,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.",
        "url": "https://finnhub.io/api/news?id=0c3032831df0bcbb79d3028c22cfba4c114172a398d92cea33daa1200a0d6bc2"
    },
    {
        "category": "company",
        "datetime": 1739871900,
        "headline": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
        "id": 132816738,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy",
        "url": "https://finnhub.io/api/news?id=3aa0b6211cbcd1908b35ad13e3417fb53a5530db15b1674f8402daf1192a5a67"
    },
    {
        "category": "company",
        "datetime": 1739868900,
        "headline": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
        "id": 132816739,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration",
        "url": "https://finnhub.io/api/news?id=c06c3437be5573b8b80b4a3b0cf24dc5901feba75524204d1702df7a2be24c5e"
    },
    {
        "category": "company",
        "datetime": 1739780400,
        "headline": "Parnassus Value Equity Fund Q4 And 2024 Annual Investment Commentary",
        "id": 132749723,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159126735/image_2159126735.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The Parnassus Value Equity Fund returned -1.48% (net) for Q4 2024, outperforming the Russell 1000 Value Index\u00e2\u0080\u0099s -1.98%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=9158e1247f9718d3e8a1093f7e7de1e04d5e89f133d52c6d4879748505ed7f82"
    },
    {
        "category": "company",
        "datetime": 1739598908,
        "headline": "Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma",
        "id": 132715981,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187983228/image_2187983228.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen\u00e2\u0080\u0099s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated \"sell\" due to declining drug franchises.",
        "url": "https://finnhub.io/api/news?id=c1908ae121981d02b68da5bc073bf916f1b609732896126c3f308191022cd89a"
    },
    {
        "category": "company",
        "datetime": 1739475019,
        "headline": "Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts",
        "id": 133191265,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion. Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn\u2019t enough to make up for declines. While Leqembi sales performed well outside the U.S. and Skyclarys",
        "url": "https://finnhub.io/api/news?id=dae94e7680e4772a283464df31e705d1e54ccce27715cb88eccc465530f3ffbd"
    },
    {
        "category": "company",
        "datetime": 1739471463,
        "headline": "Biogen Still Offering Value, RBC Says",
        "id": 133191266,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen (BIIB) showed how it has \"successfully\" reprioritized R&D and rightsized operating expenses i",
        "url": "https://finnhub.io/api/news?id=ac7421229e0dd505d9f695adba0cabbe389c32a3445a8781c522bc1490bed4ee"
    },
    {
        "category": "company",
        "datetime": 1739377129,
        "headline": "Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat",
        "id": 132694742,
        "image": "",
        "related": "BIIB",
        "source": "DowJones",
        "summary": "Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat",
        "url": "https://finnhub.io/api/news?id=27aa8f31be954227ceeb4a88abf938e8df1d51c04d7d47582a08cbb4bb59620f"
    },
    {
        "category": "company",
        "datetime": 1739364120,
        "headline": "Wall Street Lunch: Boom Goes The CPI",
        "id": 132680276,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1609437977/image_1609437977.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The January Consumer Price Index jumped +0.5% in January, accelerating from +0.4% in December",
        "url": "https://finnhub.io/api/news?id=df7b6b16222a4d9df19fe1603c4ca0739629f88a56fca2424eac04f033d1671e"
    },
    {
        "category": "company",
        "datetime": 1739364090,
        "headline": "Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript",
        "id": 132680277,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher -...",
        "url": "https://finnhub.io/api/news?id=898e23d9211dc87201b7ef9b481a371167f52c2d9333c2a5c708d0ed7b66a2e9"
    },
    {
        "category": "company",
        "datetime": 1739360580,
        "headline": "Biogen\u2019s stock slides on soft guidance and a decline in sales of MS drugs",
        "id": 132694762,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen\u2019s stock slides on soft guidance and a decline in sales of MS drugs",
        "url": "https://finnhub.io/api/news?id=8752eff66bc6053f9eb730fe92ef615715b504a682d16602e15a86204ee73628"
    },
    {
        "category": "company",
        "datetime": 1739350342,
        "headline": "Biogen Inc. 2024 Q4 - Results - Earnings Call Presentation",
        "id": 132679506,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by Biogen Inc.",
        "url": "https://finnhub.io/api/news?id=500bd2f58266f3903bcb26f7f8355118cceb46eb6e359af9313536b24ec2caa6"
    },
    {
        "category": "company",
        "datetime": 1739344980,
        "headline": "Biogen 4Q Revenue Tops Wall Street's Estimates",
        "id": 132694763,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen 4Q Revenue Tops Wall Street's Estimates",
        "url": "https://finnhub.io/api/news?id=74fb724b94cbf46ae8ce8b598adc0a911db20a0a556db730fafd169a09ac37f8"
    },
    {
        "category": "company",
        "datetime": 1739340135,
        "headline": "Market darlings Robinhood, Reddit and Applovin deliver earnings after the close",
        "id": 132681755,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Market darlings Robinhood, Reddit and Applovin deliver earnings after the close",
        "url": "https://finnhub.io/api/news?id=5c8cb51b89d35d82bfac778baac9b340cf1cf6f4b33510fa420f0d27a69ad040"
    },
    {
        "category": "company",
        "datetime": 1739150100,
        "headline": "ClearBridge Global Value Improvers Strategy Q4 2024 Commentary",
        "id": 132630188,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335295813/image_1335295813.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge Global Value Improvers Strategy outperformed its MSCI World Value benchmark during Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=04a6cc6384e5428124ad5d3acbfa978d0323850881a377f00981946ec584cad3"
    },
    {
        "category": "company",
        "datetime": 1738573458,
        "headline": "Biogen Inc. - Update on Regulatory Review of Lecanemab for Early Alzheimer's disease in the European Union",
        "id": 132520509,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD and...",
        "url": "https://finnhub.io/api/news?id=c1bd73486fe2530c637cdb2ee223448c7c0496f7832338f5284749043c92391e"
    },
    {
        "category": "company",
        "datetime": 1738308637,
        "headline": "Biogen, Eisai : EC Asks CHMP to Take Another Look at Leqembi",
        "id": 132504341,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Biogen and Eisai have hit another bump in their quest to win European regulatory approval of their Alzheimer's drug Leqembi. The companies on Friday said the European...",
        "url": "https://finnhub.io/api/news?id=a0ad8335447271826b5dcfc3a3b756e34dbfee705c861cb2927e624b6e09d62b"
    },
    {
        "category": "company",
        "datetime": 1738307640,
        "headline": "Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi",
        "id": 132534954,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi",
        "url": "https://finnhub.io/api/news?id=9a2ba48d0d9614920393fab5480e1f4ffdc1cc1312bab8d6b6f387f25ef77711"
    },
    {
        "category": "company",
        "datetime": 1738305965,
        "headline": "Europe to review safety data for Eisai-Biogen Alzheimer's drug",
        "id": 132504094,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday. The safety...",
        "url": "https://finnhub.io/api/news?id=25be6f3ff452a4f919263352b4ebc3f3420fa75955bf6764b6394a1b4ba101e1"
    },
    {
        "category": "company",
        "datetime": 1738305064,
        "headline": "Update on Regulatory Review of Lecanemab for Early Alzheimer\u2019s Disease in the European Union",
        "id": 132503998,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 -- Eisai Co., Ltd. and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as...",
        "url": "https://finnhub.io/api/news?id=16337370353012a609428accee101e02c9700d6be142ce7a8632e288ec4aad7f"
    },
    {
        "category": "company",
        "datetime": 1737997620,
        "headline": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "id": 132534957,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=31b2a31324650d91dad6ea79e7874201488ebdff3c52d9e8f95fb8e69d076d0c"
    },
    {
        "category": "company",
        "datetime": 1737975922,
        "headline": "Eisai Co., Ltd. - FDA Approves LEQEMBI IV Maintenance Dosing for the Treatment of Early Alzheimer s disease",
        "id": 132479981,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration has approved the Supplemental Biologics License Application for once every four weeks...",
        "url": "https://finnhub.io/api/news?id=dd1eea152db726341e8670ee837ab49fe99a9071df680f014f1433952abf4b4f"
    },
    {
        "category": "company",
        "datetime": 1737970920,
        "headline": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
        "id": 132534958,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Sage Rejects Biogen Bid, Launches Review of Alternatives",
        "url": "https://finnhub.io/api/news?id=7f1a9040f9399865b55776489be150745a519c828f1bf6ecb79bfa659100f033"
    },
    {
        "category": "company",
        "datetime": 1737970114,
        "headline": "Sage rejects Biogen's takeover offer, to explore strategic alternatives",
        "id": 132479461,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen and added that its board of directors has initiated a process to explore strategic...",
        "url": "https://finnhub.io/api/news?id=62c224d0f341c6cfd59f56d913d96ecabf0807d685077728da9b847335e88e22"
    },
    {
        "category": "company",
        "datetime": 1737959454,
        "headline": "Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing",
        "id": 132478471,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late...",
        "url": "https://finnhub.io/api/news?id=807a50ea0c6a2372c4ebe63ea205fd0ad2ae4f349be31f3f83a4905ea9273fad"
    },
    {
        "category": "company",
        "datetime": 1737916683,
        "headline": "US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug",
        "id": 132475742,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug...",
        "url": "https://finnhub.io/api/news?id=eb1ca8799bf1cfda13e4f36220c376eca5ac17b500df0122a8c18879ee94d2cf"
    },
    {
        "category": "company",
        "datetime": 1737916444,
        "headline": "FDA Approves LEQEMBI\u00ae (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer\u2019s Disease",
        "id": 132475743,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
        "url": "https://finnhub.io/api/news?id=438c5a13ceedd551bdfe8108030a6d2bcb07d7f6643e4914b1dc3c0d365802d9"
    },
    {
        "category": "company",
        "datetime": 1737916264,
        "headline": "FDA Approves LEQEMBI\u00ae (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
        "id": 132475745,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment \u00a0Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment...",
        "url": "https://finnhub.io/api/news?id=471080e9b88b2032f0aa7ac565ef8a5b4c731b8b7c562f804c7e4d6e2419eef9"
    },
    {
        "category": "company",
        "datetime": 1737696690,
        "headline": "Biogen: EMA and FDA examine an enhanced dosage of Spinraza",
        "id": 132453644,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Biogen announces that the European Medicines Agency has agreed to review the marketing authorization application for a higher dosage regimen of nusinersen in the treatment of spinal muscular atrophy...",
        "url": "https://finnhub.io/api/news?id=7b5fb940513e1203ed428e0ea4098fedfeab2a432d43b1bcb69659bcda31eacb"
    },
    {
        "category": "company",
        "datetime": 1737640920,
        "headline": "ClearBridge Growth Fund Q4 2024 Commentary",
        "id": 132449938,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Performance was supported in the quarter by AI-indexed semiconductor and software provider Broadcom, along with a cohort of disruptors. Read more here.",
        "url": "https://finnhub.io/api/news?id=e1e3344f16b9895b1257ed6e487791c25524d6f5b2ff9b0f7144ada59dfc5aa8"
    },
    {
        "category": "company",
        "datetime": 1737619992,
        "headline": "Biogen Gets U.S., European Reviews of Higher-Dose Spinraza",
        "id": 132448289,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "By Colin Kellaher Biogen said U.S. and European regulators will review its applications seeking approval of a higher-dose regimen of its Spinraza drug for the neuromuscular disease spinal...",
        "url": "https://finnhub.io/api/news?id=85a3cfeefb8bb8e4fcb996b69a045d25937b3706684cc8871da98c142b589de6"
    },
    {
        "category": "company",
        "datetime": 1737617463,
        "headline": "FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA",
        "id": 132448041,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. ...",
        "url": "https://finnhub.io/api/news?id=7012a0c07b894c5fe5f5e9911c5bfe054b74d6d80db74160ac5ac1904670bc96"
    },
    {
        "category": "company",
        "datetime": 1737535848,
        "headline": "Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid",
        "id": 132442317,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.",
        "url": "https://finnhub.io/api/news?id=93f960e9ee058140712fad5946ae153b0689824b4b7841b8225a43c78b91f5c6"
    },
    {
        "category": "company",
        "datetime": 1737484043,
        "headline": "Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart",
        "id": 132438763,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190703679/image_2190703679.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Discover the latest advancements in gene therapy for rare diseases like Friedreich's Ataxia and Duchenne Muscular Dystrophy, with promising new treatments.",
        "url": "https://finnhub.io/api/news?id=4b9c04102b24516f8bb42661f5382ca35d88adf447e53f4cd7ae881a64af3ab2"
    },
    {
        "category": "company",
        "datetime": 1737305685,
        "headline": "Top 4 Immunology Stocks Poised For Growth In 2025",
        "id": 132426490,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.",
        "url": "https://finnhub.io/api/news?id=89d92fb4873b2558c4d0f5f75610a8a4ee6050f99c0d8d2410f07380589e1d07"
    },
    {
        "category": "company",
        "datetime": 1737126605,
        "headline": "Biogen : at the J.P. Morgan 43rd Annual Healthcare Conference",
        "id": 132416499,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Multiple catalysts with the potential to drive LEQEMBI growth starting in 2025 MCI due to AD / Mild AD ...",
        "url": "https://finnhub.io/api/news?id=79090ecb8b546215e94f6aa0dc00e1dbe8198fd97e50076279d1df39c16748a5"
    },
    {
        "category": "company",
        "datetime": 1736936448,
        "headline": "Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders",
        "id": 132400081,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184874810/image_2184874810.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Analysis of Sage Therapeutics' financials and pipeline setbacks, including an unsolicited offer from Biogen, suggest a hold for investors. Click here to read.",
        "url": "https://finnhub.io/api/news?id=f93f44fdf6d98e179461e3cae3dd2b1803eefd1088a5971b06fe5af2990079ec"
    },
    {
        "category": "company",
        "datetime": 1736932816,
        "headline": "Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)",
        "id": 132399970,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) J.P.",
        "url": "https://finnhub.io/api/news?id=596b44a0dfff80eec18afee169ca3a8d7c0759ce5f82988b3c98500c72939086"
    },
    {
        "category": "company",
        "datetime": 1736877641,
        "headline": "Biogen CEO sees no burning need for more acquisitions",
        "id": 132396353,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said. The view...",
        "url": "https://finnhub.io/api/news?id=07a28d116c7c41dc9e77fb8721358b810314eb5ec56470899001a5ea67c26d80"
    },
    {
        "category": "company",
        "datetime": 1736829600,
        "headline": "Patient Capital Management Q4 2024 Investment Review",
        "id": 132392476,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1089222846/image_1089222846.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "During the fourth quarter of 2024, the Patient Opportunity Equity Strategy generated a total return of 8.2% net of fees. Read more here.",
        "url": "https://finnhub.io/api/news?id=4c46c494af86e68782518c362fabf40854d5bfb319dcb8fb785b81e230f6b6f1"
    },
    {
        "category": "company",
        "datetime": 1736826000,
        "headline": "Patient Capital Management Q4 2024 Commentary",
        "id": 132392179,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Patient Capital Management's Opportunity Equity Strategy surpassed the market to end up 26.5%, 150bps ahead of the S&P 500\u00e2\u0080\u0099s 25.0%. Click here to read the full fund letter.",
        "url": "https://finnhub.io/api/news?id=c91a9f164536b2ce0ecd620d1784405dbcd0ebf51731ed1a3244af49ec114ad7"
    },
    {
        "category": "company",
        "datetime": 1736795162,
        "headline": "FDA Accepts LEQEMBI\u00ae (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer\u2019s Disease",
        "id": 132390187,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
        "url": "https://finnhub.io/api/news?id=0cbd135b0a6421778065952940eea16e92d60fb7cf0daa412a3a700b00efe2d5"
    },
    {
        "category": "company",
        "datetime": 1736795105,
        "headline": "FDA Accepts LEQEMBI\u00ae (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
        "id": 132390184,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
        "url": "https://finnhub.io/api/news?id=6a645ce79eb7bffd6136b408ff4a12084a9439be3077fd517f88168a1c2f97f2"
    },
    {
        "category": "company",
        "datetime": 1736762160,
        "headline": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
        "id": 134161440,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
        "url": "https://finnhub.io/api/news?id=403461c3fdc542ef8c29a7a1aaadf9ed49bc62600769277add9a458c7fbf2d2c"
    },
    {
        "category": "company",
        "datetime": 1736750340,
        "headline": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
        "id": 132534962,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
        "url": "https://finnhub.io/api/news?id=6be856a556dea553ac3dab940f5d7b3eba909b860c862e0861af6c2195ca2cfb"
    },
    {
        "category": "company",
        "datetime": 1736680912,
        "headline": "Playing The Odds Of Anavex Alzheimer's Drug Approval",
        "id": 132382416,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1279693289/image_1279693289.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Anavex's promising Alzheimer's drug, Blarcamesine, could provide hope with its potential to slow cognitive decline, pending EMA approval. Read more here.",
        "url": "https://finnhub.io/api/news?id=d7f2f2cd0018cd4b7b4806031418618487a9642dc9c251b62d875f44f017c784"
    },
    {
        "category": "company",
        "datetime": 1736534372,
        "headline": "Biogen proposes to buy remaining stake in Sage in $442 million deal",
        "id": 132374607,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade. ...",
        "url": "https://finnhub.io/api/news?id=e33fe47c161bd55fbdbe04aec4e8af66447ff06b3e7f4c4bc8adefdba4b0edb1"
    },
    {
        "category": "company",
        "datetime": 1736485200,
        "headline": "Alzheimer\u2019s Drugs Eyed by Investors Seeking Obesity-Like Gains",
        "id": 132357051,
        "image": "https://media.zenfs.com/en/bloomberg_markets_842/29e857c7f809eb552ddff0361e37d60e",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer\u2019s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC\u2019s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam\u2019s \u2018Ugliest Building\u2019Companies including Biogen I",
        "url": "https://finnhub.io/api/news?id=ea5f36bfd3b0ac504e35d4fa86745f94ba1329858e30a5dc962073caa485c682"
    },
    {
        "category": "company",
        "datetime": 1736483843,
        "headline": "NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration",
        "id": 132359861,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91156685/image_91156685.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.",
        "url": "https://finnhub.io/api/news?id=a9f3641c501e6bded39b760bceadb26505bf805937725f8186845afbf298946d"
    },
    {
        "category": "company",
        "datetime": 1736438203,
        "headline": "Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains",
        "id": 132352308,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176382509/image_2176382509.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click for my DNLI stock update.",
        "url": "https://finnhub.io/api/news?id=b6865f1c4ce4f4925e66575258010aae3f2a62cf25ed46e91fe3c59b242b8b7c"
    },
    {
        "category": "company",
        "datetime": 1736421300,
        "headline": "ClearBridge Growth Strategy Q4 2024 Commentary",
        "id": 132348792,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385299427/image_1385299427.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the fourth quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=a062d5834c0cc6d55153a6cdeb3395c34fbd59bc73b0c15d504a33195b56b2c5"
    },
    {
        "category": "company",
        "datetime": 1736408412,
        "headline": "Biogen : Appoints Adam Feire as Head of Business Development and External Innovation",
        "id": 132346800,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice President and Head of Corporate...",
        "url": "https://finnhub.io/api/news?id=d8057b4d95051a850cb586479878f561e3f500ed52d00e463644c4c8c2665763"
    },
    {
        "category": "company",
        "datetime": 1736372429,
        "headline": "Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)\u2019s Struggles with Alzheimer\u2019s and MS Challenges?",
        "id": 132342510,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently shared his perspective on the stock [\u2026]",
        "url": "https://finnhub.io/api/news?id=b8368ad2cb74b53759625ac40d19fc3dde09ca8dcba912cd2ca6b985032e82a7"
    },
    {
        "category": "company",
        "datetime": 1736330000,
        "headline": "Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "id": 132315956,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cambridge - Biogen Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference.The webcast will...",
        "url": "https://finnhub.io/api/news?id=d8638b19e2cdb2297e852b843c9fdb0b8279a6cf35feff6094c85fd60534db23"
    },
    {
        "category": "company",
        "datetime": 1736249479,
        "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
        "id": 132302431,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
        "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    },
    {
        "category": "company",
        "datetime": 1736086947,
        "headline": "Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold",
        "id": 132279730,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.",
        "url": "https://finnhub.io/api/news?id=d6e2bada4590e6cb2a8a0f476dcec9117273e7206fb178f2a5f2430389dceffb"
    },
    {
        "category": "company",
        "datetime": 1735994700,
        "headline": "These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024",
        "id": 132269440,
        "image": "https://g.foolcdn.com/editorial/images/802476/concerned-young-person-with-head-in-hands-gazing-at-a-screen.jpg",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market.  Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index.  In order from steepest decline to narrowest, the five unloved were Intel (NASDAQ: INTC), MongoDB (NASDAQ: MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ: MCHP).",
        "url": "https://finnhub.io/api/news?id=bed035829621e2609feed513cbb164442c8e9a15e524bcff0f039634d6e106aa"
    },
    {
        "category": "company",
        "datetime": 1735984800,
        "headline": "Biogen Holds On, But Growth Slips Through Its Fingers",
        "id": 132269307,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157561333/image_157561333.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.",
        "url": "https://finnhub.io/api/news?id=cba317638d93a332d9b5b480742fb554e9fcc1a87b859e54033a9086aa156666"
    },
    {
        "category": "company",
        "datetime": 1735827947,
        "headline": "Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges",
        "id": 132242741,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Investing.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from \u201coverweight\u201d to \u201cneutral,\u201d given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, expressing concerns over Biogen's near-term revenue mix and the uphill battle in building its Alzheimer\u2019s disease franchise.",
        "url": "https://finnhub.io/api/news?id=e21fa2b179a7816e6c6ec5605d3c52866eeacccf6b6e5ed9095ffdd2f5edacec"
    },
    {
        "category": "company",
        "datetime": 1735807968,
        "headline": "INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025",
        "id": 132238619,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1554047481/image_1554047481.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "INmune Bio's XPro shows promising results in Alzheimer's, with Phase 2 data expected in 2025, potential for big pharma interest. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=bc8999ff4d784640f56044fffee39ca79cfd114343de1d0c1866ae64ea740323"
    },
    {
        "category": "company",
        "datetime": 1735742411,
        "headline": "Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term",
        "id": 132229100,
        "image": "https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "url": "https://finnhub.io/api/news?id=df70e3fcbea7583e443c7ed65dc753a05dcc7f6bd15ad5011656e6c10ea3d8aa"
    },
    {
        "category": "company",
        "datetime": 1735742220,
        "headline": "The 5 worst performing stocks on the Nasdaq 100 in 2024",
        "id": 132229013,
        "image": "",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "AI was huge in 2024. The underperformers list reflects challenges in the other sectors.",
        "url": "https://finnhub.io/api/news?id=ee11e422fa482322dff009f83a83b7a54a09ca32b8cc5cef0442dd79a6c3994c"
    },
    {
        "category": "company",
        "datetime": 1735565867,
        "headline": "Beaten Down Biogen Stock Looks Attractive At Current Levels",
        "id": 132204159,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. Click here to read I rate BIIB a Buy.",
        "url": "https://finnhub.io/api/news?id=9d2f84f3c5cf32361741ae09e904d063b6c6bf280e774c53c963c02299824733"
    },
    {
        "category": "company",
        "datetime": 1735422595,
        "headline": "Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025",
        "id": 132193532,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other cheap healthcare stocks. The Resilience and Challenges of Global Healthcare Spending Investing in healthcare equities is typically seen as protective during [\u2026]",
        "url": "https://finnhub.io/api/news?id=594ef938707033b2b313b3b585353dd3e6cf7f99396cee31f9bdee2df9c8a44d"
    },
    {
        "category": "company",
        "datetime": 1734963420,
        "headline": "Wall Street Lunch: Nordstrom To Go Private",
        "id": 132122216,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468727791/image_1468727791.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Department store chain Nordstrom (JWN) has accepted a $6.25 billion all-cash buyout offer to end its 53-year run as a publicly traded company.",
        "url": "https://finnhub.io/api/news?id=cda1d07dc4301357ff00adf0d7f794a87074699afbb53803ed3c773f0b75d715"
    },
    {
        "category": "company",
        "datetime": 1734948457,
        "headline": "Biogen Faces Multiple Analyst Downgrades in December 2024",
        "id": 132116962,
        "image": "https://media.zenfs.com/en/us.finance.gurufocus/3dacfff8652bb48efcbb9dbda59a319b",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Skepticism Grows as Sales Projections and Pipeline Prospects Dim",
        "url": "https://finnhub.io/api/news?id=f901e334ac65cdc27c00f2301f6dea9e516489f80f3ed1780869567948fb6f07"
    },
    {
        "category": "company",
        "datetime": 1734705894,
        "headline": "BMO cuts rating on Merck and Biogen, on lack of near term catalyst",
        "id": 132077718,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.",
        "url": "https://finnhub.io/api/news?id=d059b0bd5c61e2c8c0d94c46c4569ffcaf65d5bf70d191364489f84223618cf3"
    },
    {
        "category": "company",
        "datetime": 1734674700,
        "headline": "Impax Ellevate Global Women's Leadership Fund Q3 2024 Commentary",
        "id": 132070668,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1194611027/image_1194611027.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The Impax Global Women\u00e2\u0080\u0099s Leadership Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=320e5055829731ea3de7d0e76a2ecae2e07406bb21bcd74c624f2224ff955e2c"
    },
    {
        "category": "company",
        "datetime": 1734439293,
        "headline": "Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)",
        "id": 132027250,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1450677556/image_1450677556.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Viridian Therapeutics, Inc.'s stock soars on positive trial results, analysts bullish on FDA approval in 2026. Read more on VRDN stock prospects.",
        "url": "https://finnhub.io/api/news?id=5dd023fab80d156865a2de4df7816a9ebe637325ee8d1c20ba09ec6bd7674c67"
    },
    {
        "category": "company",
        "datetime": 1734413297,
        "headline": "Biogen downgraded to Hold by Stifel - slower progress than expected",
        "id": 132022540,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Stifel is lowering its recommendation for US drug company Biogen to hold from buy due to a struggling year following a slow rollout of Alzheimer's drug lecanemab. That's according to an analysis....",
        "url": "https://finnhub.io/api/news?id=2f70de68707efa9bc000cad639e21bc111ebaf4d5a3e6670d64cf6f2cc7adb65"
    },
    {
        "category": "company",
        "datetime": 1734372966,
        "headline": "Stifel downgrades Biogen on slow Alzheimer\u2019s drug launch, uncertainty ahead",
        "id": 132014537,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Investing.com -- Stifel downgraded Biogen Inc (NASDAQ:BIIB) stock to \u201chold\u201d from \u201cbuy\u201d as it noted the company was grappling with a challenging year due to a slow rollout of its Alzheimer\u2019s drug, lecanemab.",
        "url": "https://finnhub.io/api/news?id=e5b867040d470989a2c1ce2627978dbd8f7b0ced42cae21bd1dc3f61c63f835c"
    },
    {
        "category": "company",
        "datetime": 1734362801,
        "headline": "Netflix, Ford, Biogen: Trending tickers",
        "id": 132012860,
        "image": "https://s.yimg.com/ny/api/res/1.2/l7biPs1A7i8mm29QkrJ3Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/4e437260-bbc1-11ef-a77e-b166291dc313",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Morning Brief anchors Seana Smith and Brad Smith discuss Wall Street's latest stock analyst recommendations. Loop Capital downgraded Netflix (NFLX) stock to Hold from Buy while raising the price target to $950 per share, arguing the stock is approaching fair value. Meanwhile, Oppenheimer analysts raised their price target to $1,065 per share, highlighting the company's expansion into live events. Ford (F) shares declined after Jefferies downgraded the automaker to Underperform from Hold. The firm cited several challenges, including inventory overhang and strategic complexities surrounding its European business operations. Additionally, Stifel analysts reduced Biogen's (BIIB) rating to Hold from Buy, noting an absence of clinical catalysts for the upcoming year. To watch more expert insights and analysis on the latest market action, check out more Morning Brief\u00a0here. This post was written by Angel Smith",
        "url": "https://finnhub.io/api/news?id=c1c49cf301f9dc1eb2f5a16754cb148b6e23a89312aebb85e116a2f780c371d9"
    },
    {
        "category": "company",
        "datetime": 1734360011,
        "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
        "id": 132014539,
        "image": "https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "url": "https://finnhub.io/api/news?id=56554951293025d8fabf2768155980d09431875dcb4c276a497caca6987dfab2"
    },
    {
        "category": "company",
        "datetime": 1734350100,
        "headline": "American Century Ultra Fund Q3 2024 Commentary",
        "id": 132012715,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160928890/image_1160928890.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "The broad U.S. stock market posted solid gains that saw a reversal of trends from the first half of the year. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=30d50aff6e121c21c73f070a2cf619d16f40363f6bcf0607404d1f906adf3825"
    },
    {
        "category": "company",
        "datetime": 1734022788,
        "headline": "Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?",
        "id": 131934892,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 20...",
        "url": "https://finnhub.io/api/news?id=d3151ec10ba4a8f6e9ad457257b62d0298474df80b531caaf2a7806cac925742"
    },
    {
        "category": "company",
        "datetime": 1734008554,
        "headline": "Private Medicare plans must cover Biogen's ALS drug, US agency says",
        "id": 131931482,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of...",
        "url": "https://finnhub.io/api/news?id=5834f4d4fd47bc47767b09ccd61e1fcf77d886501b12fcecf71721adf1f36371"
    },
    {
        "category": "company",
        "datetime": 1733936820,
        "headline": "Biogen Inc. stock rises Wednesday, still underperforms market",
        "id": 131949085,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock rises Wednesday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=12c6bb4b90ae008941f8b5013d179bf96f46fa239d31518ccb6bd34686e939a3"
    },
    {
        "category": "company",
        "datetime": 1733919015,
        "headline": "Biogen reinstated with a Neutral at BofA",
        "id": 131926202,
        "image": "https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is \u201ca cheaper name,\u201d mostly because Leqembi for Alzheimer\u2019s has launched \u201ctoo slowly,\u201d the analyst tells investors. The downside \u201cfeels limited,\u201d so it is worth tracking as the Leqembi launch picks up, the analyst added. Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on BIIB: VOO ETF Update,",
        "url": "https://finnhub.io/api/news?id=f4f9e1e7155df32dafb01494cf3b7ad2201d861feea0a25746452be4d95731a0"
    },
    {
        "category": "company",
        "datetime": 1733837520,
        "headline": "Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock",
        "id": 131902468,
        "image": "https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.",
        "url": "https://finnhub.io/api/news?id=6ed1091e8731e046d70407fb2d373f78906de1514135d9f7c9a1c6c67dde1473"
    },
    {
        "category": "company",
        "datetime": 1733769853,
        "headline": "Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown",
        "id": 131894001,
        "image": "https://media.zenfs.com/en/Benzinga/7ebf94f4bb8b321649be7ef19d065ecf",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company\u2019s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption. The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could pus",
        "url": "https://finnhub.io/api/news?id=19605ef572d7bd5fb594531b7b72ef5a065b75540e57d354445c2e8a9497eda5"
    },
    {
        "category": "company",
        "datetime": 1733765221,
        "headline": "Biogen cut at Jefferies as '2025 has a tough setup'",
        "id": 131894004,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025.  Analysts highlighted that Biogen\u2019s Alzheimer's drug, Leqembi, faces slower-than-expected growth, with Jefferies lowering its 2025 sales estimates to $466 million, below the consensus of $494 million.  \u201cWe move to HOLD as 2025 has a tough setup: modest Leqembi (we're below consensus) and Skyclarys US (mostly penetrated), and real need for more pipeline and serious BD to get investors re-engaged,\u201d said Jefferies.",
        "url": "https://finnhub.io/api/news?id=245f05912baf343ae89be4f6979a6c65e20a420a50985078767169616efdb78b"
    },
    {
        "category": "company",
        "datetime": 1733735024,
        "headline": "Tax-Loss Stocks To Sell Before Everyone Else Does",
        "id": 131869198,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795167728/image_1795167728.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Prepare for tax-loss selling at year-end by considering selling underperforming stocks like Celanese, Walgreens, and Intel. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=f1721d0d8f7ac3f6583890510ac501d4aeac1ccc40598c7bb3e71a898eb673eb"
    },
    {
        "category": "company",
        "datetime": 1733730245,
        "headline": "Biogen : Appoints Tim Power as Head of Investor Relations",
        "id": 131868179,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "today announced the appointment of Tim Power as Vice President, Head of Investor Relations, effective December 9, 2024. Mr. Power will report to Michael McDonnell, Executive Vice President and Chief...",
        "url": "https://finnhub.io/api/news?id=aa477e1a92f3b8d17cde0294cbd5ef6e29af7cb60df81d9ccf39ecaaf319b849"
    },
    {
        "category": "company",
        "datetime": 1733390700,
        "headline": "Harbor Mid Cap Value Fund Q3 2024 Commentary",
        "id": 131791652,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "During the third quarter, the Harbor Mid Cap Value Fund (Institutional Class) slightly lagged its benchmark, the Russell Midcap Value Index.",
        "url": "https://finnhub.io/api/news?id=a3922113f4d1171ad567eb8efb34258a453ea2dd7ad0252cfb2498435f288c5e"
    },
    {
        "category": "company",
        "datetime": 1733355060,
        "headline": "\"LEQEMBI\u00ae\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
        "id": 131794521,
        "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (A\u03b2) monoclonal antibody \"LEQEMBI\u00ae\" (lecanemab) for the treatment of early Alzheimer's disease (AD)*.",
        "url": "https://finnhub.io/api/news?id=5c8373acb0b20c1d5d128d09e99cae858fdc838164c3776d5393120ff9218c36"
    },
    {
        "category": "company",
        "datetime": 1733350925,
        "headline": "\"LEQEMBI\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
        "id": 131772944,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "- Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk in Mexico has approved humanized anti-soluble aggregated amyloid-beta monoclonal...",
        "url": "https://finnhub.io/api/news?id=eea1f9ee70a5fe02abd1755ea12369df18c591b5385b73fc758dfb173f3cab17"
    },
    {
        "category": "company",
        "datetime": 1733276100,
        "headline": "Columbia Contrarian Core Fund Q3 2024 Commentary",
        "id": 131763279,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2066272044/image_2066272044.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Institutional Class shares of Columbia Contrarian Core Fund returned 3.50% (net) during Q3 2024 underperforming the benchmark. Click here to read the full commentary.  ",
        "url": "https://finnhub.io/api/news?id=4448573f28abbcd9b387b3b33abd43638e13b96312c195ce517158359eeea9a6"
    },
    {
        "category": "company",
        "datetime": 1733228129,
        "headline": "Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript",
        "id": 131755466,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Biogen Inc. (NASDAQ:BIIB) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ETCompany ParticipantsAlisha Alaimo -...",
        "url": "https://finnhub.io/api/news?id=ae7638e21d69a7e50e5be9a8bda2db5e071c433f92a6fd2c190a0082fba395df"
    },
    {
        "category": "company",
        "datetime": 1732891212,
        "headline": "Why This 1 Value Stock Could Be a Great Addition to Your Portfolio",
        "id": 131709744,
        "image": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "url": "https://finnhub.io/api/news?id=b95e4047c3e187d9df28fe56d9adbf243d6a639561c4bc8b6a5042999f086196"
    },
    {
        "category": "company",
        "datetime": 1732792081,
        "headline": "Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?",
        "id": 131687459,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheapest stocks to buy on Robinhood. While the market has been on an upward trajectory for nearly two years now, the combination of seasonal [\u2026]",
        "url": "https://finnhub.io/api/news?id=cd4e95945bdcf179e3f9906436af39e7551f43cba4e9b4b54e815658355dae3d"
    },
    {
        "category": "company",
        "datetime": 1732783065,
        "headline": "Eisai Co., Ltd. - LEQEMBI for the Treatment of Alzheimer's disease Launched in South Korea",
        "id": 131684561,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody 'LEQEMBI' has been launched in South Korea.LEQEMBI...",
        "url": "https://finnhub.io/api/news?id=8a308fbb6aae702e22d5f3e7379f1f25830186bd3538e9b547a14c7bd2c385a2"
    },
    {
        "category": "company",
        "datetime": 1732753860,
        "headline": "\"LEQEMBI\u00ae\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
        "id": 131676080,
        "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the humanized anti-soluble aggregated amyloid-beta (A\u03b2) monoclonal antibody \"LEQEMBI\u00ae\" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's diseas",
        "url": "https://finnhub.io/api/news?id=31e53fbd21e99cdbbbe84b2c8c3037de31b2eba7196f7dd9b137a788aed1f662"
    },
    {
        "category": "company",
        "datetime": 1732735492,
        "headline": "Biogen : \u201cLEQEMBI\u00ae\u201d (Lecanemab) for the Treatment of Alzheimer\u2019s Disease Launched in South Korea",
        "id": 131674572,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., November 28, 2024 - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI\u00ae has been...",
        "url": "https://finnhub.io/api/news?id=f45dcad90a10931b73b4e889a45ad1774b005452e3112d634aa38295d3e33592"
    },
    {
        "category": "company",
        "datetime": 1732716902,
        "headline": "Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?",
        "id": 131676081,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. The Evolving Landscape of Global Healthcare Spending and Innovation The healthcare industry remains a vital and resilient sector which is driven [\u2026]",
        "url": "https://finnhub.io/api/news?id=7c964c7e54d9638d21cca04495553a66e2f13162783097cfbfc472b96e54c98d"
    },
    {
        "category": "company",
        "datetime": 1732649022,
        "headline": "Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?",
        "id": 131652333,
        "image": "",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?",
        "url": "https://finnhub.io/api/news?id=90d8ab6a663f1a994b23b9c09a625d8f05ca9331088afe822a86415b9c96b7a8"
    },
    {
        "category": "company",
        "datetime": 1732588581,
        "headline": "Cassana Sciences collapsed after study disappointment in Alzheimer's",
        "id": 131629376,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cassava Sciences' Phase 3 study of the drug candidate simufilam in patients with mild to moderate Alzheimer's disease , has shown no significant reduction in cognitive or functional impairment...",
        "url": "https://finnhub.io/api/news?id=0f805b1ac0a71a69171acce36f1e42cb94d695402fe409b612b8abecb4f20312"
    },
    {
        "category": "company",
        "datetime": 1732587125,
        "headline": "Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the \"AD-DMT Registry\" in Japan",
        "id": 131629239,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "- Eisai Co., Ltd. and Biogen Japan Ltd. announced today that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Psychiatry to conduct apolipoprotein E ...",
        "url": "https://finnhub.io/api/news?id=4c7624c94064ad774c3a8245d50130c895cfaad1b41a59d2f8a5d76ef143c9a5"
    },
    {
        "category": "company",
        "datetime": 1732534515,
        "headline": "Biogen: Jefferies confirms its target as it awaits Ocrevus",
        "id": 131625257,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Jefferies confirms its Buy rating on Biogen shares, with an unchanged price target of $250. The analyst reports that crucial data from a Phase III trial of Ocrevus could arrive in the first half of...",
        "url": "https://finnhub.io/api/news?id=f15801c358037b3c29a73a3cb9d4f440a34d1e94ffb5ad4366758cdc435176ad"
    },
    {
        "category": "company",
        "datetime": 1732279541,
        "headline": "Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock",
        "id": 131563445,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently made a list of Goldman Sachs\u2019 Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial [\u2026]",
        "url": "https://finnhub.io/api/news?id=3523d3f170465ffa6caf46a6bcc1ea6a9fa88fe75a55de79aaf042224e8ccbad"
    },
    {
        "category": "company",
        "datetime": 1732275912,
        "headline": "Biogen price target lowered to $207 from $251 at Mizuho",
        "id": 131563448,
        "image": "",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Mizuho lowered the firm\u2019s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. Biogen\u2019s Q3 contained no major surprises, but Mizuho cut the price target on a slow Leqembi launch, the analyst tells investors in a research note. The firm continues to see the Biogen story as a longer term positive, largely on how and when the Leqembi launch could accelerate. Published first on Th",
        "url": "https://finnhub.io/api/news?id=6a39563f4916dcb5496900f4c1b41fab16d90d8b1d3be395debe5f4be80b18d0"
    },
    {
        "category": "company",
        "datetime": 1732208820,
        "headline": "Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
        "id": 131611819,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=6af1ab354f3f467aa3f9c18392418c217e32a2f9188ed8eefabfc43408b5b59b"
    },
    {
        "category": "company",
        "datetime": 1732127549,
        "headline": "Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside",
        "id": 131516228,
        "image": "https://media.zenfs.com/en/Benzinga/3de241384d40b386a866beb16813a4d2",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The",
        "url": "https://finnhub.io/api/news?id=e32d5f5b6653ba3a52eeeb67fb6116ed28bc34459ea5c2c3f56269a289256dbf"
    },
    {
        "category": "company",
        "datetime": 1732061166,
        "headline": "Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now",
        "id": 131497116,
        "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics field [\u2026]",
        "url": "https://finnhub.io/api/news?id=75438db1bb24cbe51ae71e4eb16586db7982d27712bbd387c8c4e320486d02ee"
    },
    {
        "category": "company",
        "datetime": 1732035967,
        "headline": "Biogen : to Participate in the 7th Annual Evercore HealthCONx Conference",
        "id": 131492640,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "Cambridge, MA, - - Biogen Inc. announced today that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the 7th Annual Evercore HealthCONx Conference. The...",
        "url": "https://finnhub.io/api/news?id=92581c6dc2ebd096a4d0b2d8877b4cc1d269de9af9edf771b3ee9eb2e5f73a36"
    },
    {
        "category": "company",
        "datetime": 1732010111,
        "headline": "Samsung Bioepis and Biogen Receive European Commission Approval for Aflibercept Biosimilar, OPUVIZ",
        "id": 131471470,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "INCHEON, CAMBRIDGE - Samsung Bioepis Co., Ltd. and Biogen Inc. today announced that the European Commission has approved OPUVIZ 40 mg/mL solution for injection in a vial, a biosimilar referencing...",
        "url": "https://finnhub.io/api/news?id=2089d2dbcdf1ceafea9e0d0567baa1db07132a4273749b2a38d7a0d44f5bf9d2"
    },
    {
        "category": "company",
        "datetime": 1731996000,
        "headline": "Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity",
        "id": 131465273,
        "image": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy",
        "url": "https://finnhub.io/api/news?id=d834ea3b92155cc3d3ee0132551abd9fb02aad5463c9bbf063ff70ef8cdf61c5"
    },
    {
        "category": "company",
        "datetime": 1731985455,
        "headline": "Biogen: positive phase 3 results in lupus",
        "id": 131465712,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "UCB and Biogen announce that they have presented positive detailed results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus...",
        "url": "https://finnhub.io/api/news?id=45a4ed140a3923715bcaa003220d6a4a17fb86e8acbacb0051513f51177c6656"
    },
    {
        "category": "company",
        "datetime": 1731953922,
        "headline": "Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026",
        "id": 131460668,
        "image": "https://media.zenfs.com/en/Benzinga/819dd36396d32967b695c60994bfa819",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer\u2019s drug Leqembi\u2019s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue. Leqembi\u2019s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million. Although investors ar",
        "url": "https://finnhub.io/api/news?id=141d91c15bda60ad8539f229fffa4d106fedfe063e09dd8d212989653fd63be5"
    },
    {
        "category": "company",
        "datetime": 1731947432,
        "headline": "Needham downgrades Biogen on slow growth of Alzheimer's drug",
        "id": 131460669,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.",
        "url": "https://finnhub.io/api/news?id=cedaa346f38746cb5561d79e5fa721936a44af3206859f5e3c407593c11f853f"
    },
    {
        "category": "company",
        "datetime": 1731931200,
        "headline": "Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ\u2122",
        "id": 131440771,
        "image": "",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "OPUVIZ\u2122 is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen\u2019s partnershipEC approval based on robust totality of evidence confirming biosimilarity to reference aflibercept in terms of quality, efficacy, and safety INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European",
        "url": "https://finnhub.io/api/news?id=af2cad451c3f54d73c40c9a6b924817821457ca0415a0bb8a1a9076a9ea38a84"
    },
    {
        "category": "company",
        "datetime": 1731921947,
        "headline": "Is Biogen Inc. (BIIB)\u00a0A Cheap NASDAQ Stock To Invest In Now?",
        "id": 131440772,
        "image": "https://media.zenfs.com/en/insidermonkey.com/19f06d2f1156978c403925aa82274a77",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other cheap NASDAQ stocks to invest in now. How Did The Stock Market Perform In Q3 2024? The stock market has been following an [\u2026]",
        "url": "https://finnhub.io/api/news?id=d5a5ce366739e0f9d710f25cece8a28d0341876fe708912147a250535dda22ff"
    },
    {
        "category": "company",
        "datetime": 1731903372,
        "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
        "id": 131438224,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/601800909/image_601800909.jpg?io=getty-c-w1536",
        "related": "BIIB",
        "source": "SeekingAlpha",
        "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
        "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91"
    },
    {
        "category": "company",
        "datetime": 1731679440,
        "headline": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
        "id": 131375206,
        "image": "https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.",
        "url": "https://finnhub.io/api/news?id=1350f1a765898814cfdafda3a8ff5af9fde1eb04128938c4481e9bf7fc7b9a03"
    },
    {
        "category": "company",
        "datetime": 1731612030,
        "headline": "European committee takes a second look at Alzheimer's drug and now says it should be approved",
        "id": 131357762,
        "image": "https://s.yimg.com/ny/api/res/1.2/smQO.QVFqeLNNTj4rBC_ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/ap_finance_articles_694/41d9ef9c1c260a31071a7987c2de447d",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "A European regulatory committee now recommends approval of the Alzheimer\u2019s treatment lecanemab a few months after rejecting the drug.  Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer\u2019s disease.  The European Commission is now expected to make a marketing authorization decision in the next few months.",
        "url": "https://finnhub.io/api/news?id=cdaf2e23afbeaa74c0cd66c33f07d1f78ab78d2c117736d7330a4dc77f0d3950"
    },
    {
        "category": "company",
        "datetime": 1731610380,
        "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
        "id": 131357763,
        "image": "https://s.yimg.com/ny/api/res/1.2/QrvejPduXGfjO6QTtPWJsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a741676153df2123cda83c0fb107464e",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
        "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787"
    },
    {
        "category": "company",
        "datetime": 1731608940,
        "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
        "id": 131357765,
        "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (A\u03b2) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive imp",
        "url": "https://finnhub.io/api/news?id=45fc91f78acbb7639d09d6ad18b96e66496c08b8b467c0c13957bf3be118f919"
    },
    {
        "category": "company",
        "datetime": 1731597840,
        "headline": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
        "id": 131356405,
        "image": "https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.",
        "url": "https://finnhub.io/api/news?id=9ff15fb98645c3acd3038c96b95ca2c77c204a7202b4c5ebce9ec59b9061a240"
    },
    {
        "category": "company",
        "datetime": 1731596084,
        "headline": "Citi initiates coverage on 5 new biotech stocks",
        "id": 131350566,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).",
        "url": "https://finnhub.io/api/news?id=2f718d9f8051ba228518a6bfcb6a3d3cad58019f54abc513adba387c2f4bd164"
    },
    {
        "category": "company",
        "datetime": 1731591360,
        "headline": "RNA Stock Hits Record High on Entering the Cardiac Disease Space",
        "id": 131350093,
        "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.",
        "url": "https://finnhub.io/api/news?id=fae4c2aabc2bce10888ccd6388b98b3b19b22bff0e0c52544909b734d09a7037"
    },
    {
        "category": "company",
        "datetime": 1731590460,
        "headline": "Biogen\u2019s stock rises after E.U. regulator reverses negative view of Alzheimer\u2019s drug",
        "id": 131428429,
        "image": "",
        "related": "BIIB",
        "source": "MarketWatch",
        "summary": "Biogen\u2019s stock rises after E.U. regulator reverses negative view of Alzheimer\u2019s drug",
        "url": "https://finnhub.io/api/news?id=846aaa55906de1faa41a1e272836baf8f2af93156bfabaf1c63113402b04e3b3"
    },
    {
        "category": "company",
        "datetime": 1731586524,
        "headline": "Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug",
        "id": 131352257,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "By Colin Kellaher A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said...",
        "url": "https://finnhub.io/api/news?id=7ae519d7794c529d94e757f3e49141787711e6d281fd1e4e0c8a9ad180da5c10"
    },
    {
        "category": "company",
        "datetime": 1731583443,
        "headline": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer\u2019s Disease",
        "id": 131351218,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 -- Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use of the...",
        "url": "https://finnhub.io/api/news?id=d88c443fe20fe4e4411228caa920ecedbd4d17049795cbc2782c554645bc18c1"
    },
    {
        "category": "company",
        "datetime": 1731503580,
        "headline": "Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut",
        "id": 131328949,
        "image": "https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.",
        "url": "https://finnhub.io/api/news?id=ad8eaf01260ee17a80723d724bae12e0119933678e44dbaa7ccded1f25792c12"
    },
    {
        "category": "company",
        "datetime": 1731436620,
        "headline": "Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View",
        "id": 131310038,
        "image": "",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.",
        "url": "https://finnhub.io/api/news?id=567a117c37f063f9ae9a78a85d721cf605b3ad1fa3c97015d707122754945aa7"
    },
    {
        "category": "company",
        "datetime": 1731422411,
        "headline": "Here's Why Biogen Inc. (BIIB) is a Strong Value Stock",
        "id": 131307656,
        "image": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "url": "https://finnhub.io/api/news?id=1ce00798ed78ef96ce487f790939cb10e0c8e22a97ec48e2da0f51d8db6b0185"
    },
    {
        "category": "company",
        "datetime": 1730912340,
        "headline": "Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated",
        "id": 131130320,
        "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.",
        "url": "https://finnhub.io/api/news?id=f4a9f301277eecee3d1af8fea3b1c54e8edfe0c5ea9e3bad122e37b70710cf86"
    },
    {
        "category": "company",
        "datetime": 1730911213,
        "headline": "BIIB vs. MYGN: Which Stock Is the Better Value Option?",
        "id": 131130322,
        "image": "https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "BIIB vs. MYGN: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=ab554ba7436f42ef0f610fa3eeabfc80677ef83d84a05c52e3028ba195ee8d25"
    },
    {
        "category": "company",
        "datetime": 1730817616,
        "headline": "Are Investors Undervaluing Biogen (BIIB) Right Now?",
        "id": 131104784,
        "image": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
        "url": "https://finnhub.io/api/news?id=89e51195b8c9de841dacd3cada53eb289f0a09118296b899060e17539fc31501"
    },
    {
        "category": "company",
        "datetime": 1730730906,
        "headline": "Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner",
        "id": 131070185,
        "image": "https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.",
        "url": "https://finnhub.io/api/news?id=da7c1f7a9ab6eb5481f25eb0a10d792aa51977b4d89ab0a71cfd1a1d7d895dc6"
    },
    {
        "category": "company",
        "datetime": 1730516280,
        "headline": "Executive reshuffles: BIIB, USB and WES",
        "id": 131012607,
        "image": "",
        "related": "BIIB",
        "source": "Seeking Alpha",
        "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.",
        "url": "https://finnhub.io/api/news?id=5bea9354700961497470aa34ba4330dbcc10722b4120050fac21bc915ee361cb"
    },
    {
        "category": "company",
        "datetime": 1730457594,
        "headline": "Eisai Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease under the Fast Track Status",
        "id": 130955547,
        "image": "",
        "related": "BIIB",
        "source": "Finnhub",
        "summary": "TOKYO, CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for...",
        "url": "https://finnhub.io/api/news?id=533b0c1c34dd6d76ef24a0012699b048e6ac54c6af438f23fbc602c66980d386"
    },
    {
        "category": "company",
        "datetime": 1730456305,
        "headline": "Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
        "id": 130954127,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
        "related": "BIIB",
        "source": "Yahoo",
        "summary": "Biogen ( NASDAQ:BIIB ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.47b (down 2.5% from 3Q 2023). Net...",
        "url": "https://finnhub.io/api/news?id=a2abef3851e7e49e32a0114fc1f034e3b637f1c25253ebaaeb0a2e0e3154e133"
    },
    {
        "category": "company",
        "datetime": 1730439720,
        "headline": "QQQ ETF Update, 11/1/2024",
        "id": 130960164,
        "image": "",
        "related": "BIIB",
        "source": "TipRanks",
        "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.",
        "url": "https://finnhub.io/api/news?id=b5732245fcf20c4cf5a78d7f04aa3abfdc1f1a83638444ac4da101fa4d19fb69"
    }
]